North America Cancer Immunotherapy Market Size to register a growth of 13.1% CAGR

16-01-2018 | Report Format: Electronic (PDF)

Growth, Trends and Report Highlights

According to a new report North America Cancer Immunotherapy Market, published by KBV research, the North America Cancer Immunotherapy Market would witness market growth of 13.1% CAGR during the forecast period (2018 – 2024).

The US market would dominate the North America Cytokines & Immunomodulators Cancer Immunotherapy Market by 2024; growing at a CAGR of 10.6 % during the forecast period. The Canada market is expected to witness a CAGR of 13.2% during (2018 - 2024). Additionally, The Mexico market is expected to witness a CAGR of 12.5% during (2018 - 2024).

The Hospitals market dominated the North America Cancer Immunotherapy Market by End User 2017, thereby, achieving a market value of $25,898.6 million by 2024The Clinics market is expected to witness a CAGR of 12.7% during (2018 - 2024). Additionally, The Other End User market is expected to witness highest CAGR of 13.4% during (2018 - 2024).

The Monoclonal Antibodies market dominated the Mexico Cancer Immunotherapy Market by Technology 2017, growing at a CAGR of 14.5 % during the forecast period. The Cytokines & Immunomodulators market is expected to witness a CAGR of 12.5% during (2018 - 2024). Additionally, The Other Technology market is expected to witness highest CAGR of 14.8% during (2018 - 2024).

Full Report: https://www.kbvresearch.com/north-america-cancer-immunotherapy-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd